Chardan Capital Decreases Earnings Estimates for MeiraGTx

MeiraGTx Holdings plc (NASDAQ:MGTX) – Stock analysts at Chardan Capital cut their FY2025 EPS estimates for shares of MeiraGTx in a report released on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings of ($1.05) per share for the year, down from their previous estimate of $0.25. Chardan Capital currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share. Chardan Capital also issued estimates for MeiraGTx’s FY2026 earnings at ($0.95) EPS.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.13). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The company had revenue of $1.93 million for the quarter, compared to the consensus estimate of $4.44 million.

Separately, Royal Bank of Canada boosted their price target on shares of MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a research report on Monday, March 17th.

MeiraGTx Stock Down 1.0%

MGTX opened at $4.99 on Monday. The firm has a market cap of $401.02 million, a price-to-earnings ratio of -4.12, a PEG ratio of 0.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The firm’s 50-day simple moving average is $6.29 and its 200-day simple moving average is $6.35. MeiraGTx has a twelve month low of $3.85 and a twelve month high of $8.75.

Institutional Trading of MeiraGTx

Several institutional investors and hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. boosted its position in shares of MeiraGTx by 106.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company’s stock worth $30,000 after purchasing an additional 2,515 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in MeiraGTx by 68.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company’s stock valued at $30,000 after purchasing an additional 2,016 shares during the last quarter. GAMMA Investing LLC lifted its stake in MeiraGTx by 3,606.7% in the first quarter. GAMMA Investing LLC now owns 4,448 shares of the company’s stock valued at $30,000 after buying an additional 4,328 shares during the period. CWM LLC lifted its stake in MeiraGTx by 1,737.7% in the first quarter. CWM LLC now owns 8,674 shares of the company’s stock valued at $59,000 after buying an additional 8,202 shares during the period. Finally, Ieq Capital LLC bought a new position in MeiraGTx during the first quarter worth about $83,000. Institutional investors own 67.48% of the company’s stock.

Insider Buying and Selling

In related news, CEO Alexandria Forbes sold 47,500 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $5.34, for a total value of $253,650.00. Following the transaction, the chief executive officer now directly owns 1,408,983 shares in the company, valued at $7,523,969.22. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total transaction of $144,000.00. Following the completion of the transaction, the chief financial officer now directly owns 882,494 shares in the company, valued at approximately $5,294,964. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.50% of the stock is owned by corporate insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.